92 related articles for article (PubMed ID: 15266019)
1. Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines.
Kim TE; Park SY; Hsu CH; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Aug; 66(2):285-92. PubMed ID: 15266019
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration.
Grove KL; Guo X; Liu SH; Gao Z; Chu CK; Cheng YC
Cancer Res; 1995 Jul; 55(14):3008-11. PubMed ID: 7606719
[TBL] [Abstract][Full Text] [Related]
3. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
4. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Lam W; Bussom S; Cheng YC
Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
[TBL] [Abstract][Full Text] [Related]
5. Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and beta-D-arabinofuranosylcytosine).
Lam W; Park SY; Leung CH; Cheng YC
Mol Pharmacol; 2006 May; 69(5):1607-14. PubMed ID: 16481390
[TBL] [Abstract][Full Text] [Related]
6. The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine.
Lam W; Leung CH; Bussom S; Cheng YC
Mol Pharmacol; 2007 Sep; 72(3):536-44. PubMed ID: 17565005
[TBL] [Abstract][Full Text] [Related]
7. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
8. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.
Nivens MC; Felder T; Galloway AH; Pena MM; Pouliot JJ; Spencer HT
Cancer Chemother Pharmacol; 2004 Feb; 53(2):107-15. PubMed ID: 14605862
[TBL] [Abstract][Full Text] [Related]
9. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells.
Grove KL; Cheng YC
Cancer Res; 1996 Sep; 56(18):4187-91. PubMed ID: 8797590
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
12. A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.
Chou KM; Kukhanova M; Cheng YC
J Biol Chem; 2000 Oct; 275(40):31009-15. PubMed ID: 10906132
[TBL] [Abstract][Full Text] [Related]
13. Troxacitabine prodrugs for pancreatic cancer.
Adema AD; Radi M; Daft J; Narayanasamy J; Hoebe EK; Alexander LE; Chu CK; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1073-7. PubMed ID: 18058539
[TBL] [Abstract][Full Text] [Related]
14. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines.
Borovitskaya AE; D'Arpa P
Oncol Res; 1998; 10(5):271-6. PubMed ID: 9802062
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
16. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient.
Adams DJ; Wahl ML; Flowers JL; Sen B; Colvin M; Dewhirst MW; Manikumar G; Wani MC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):145-54. PubMed ID: 16001167
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
18. Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines.
Janss AJ; Levow C; Bernhard EJ; Muschel RJ; McKenna WG; Sutton L; Phillips PC
Exp Cell Res; 1998 Aug; 243(1):29-38. PubMed ID: 9716446
[TBL] [Abstract][Full Text] [Related]
19. [Troxacitabine].
Gourdeau H; Jolivet J
Bull Cancer; 2004 Mar; 91(3):213-8. PubMed ID: 15171046
[TBL] [Abstract][Full Text] [Related]
20. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
